Chimerism and transplant-related diagnostics

Leukemia

Volumn 20, Issue 8, 2006, Pages 1358-1360

  Muller Berat N ^a   Lion, T ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL KILLER CELL RECEPTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; AWARENESS; BACTERIAL INFECTION; CHIMERA; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; EDITORIAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HLA MATCHING; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL EXPERT; MYCOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 33746163435     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404268     Document Type: Editorial

References (37)

1. Lion T, Muller B N. Chimerism testing after allogeneic stem cell transplantation: Importance of timing and optimal technique for chimerism testing in different clinical-biological situations. Leukemia 1999; 13: 2059.
2. Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S et al. Kinetics of chimaerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: Implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13: 2060-2069.
3. Peters C, Matthes-Martin S, Fritsch G, Holter W, Lion T, Witt V et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: Evaluation of early monitring of engraftment. Leukemia 13; 2070: 1999.
4. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children. Leukemia 1999; 13: 2079-2086.
5. Lion T. Chimerism testing after allogeneic stem cell transplantation: importance of timing and optimal technique for chimerism testing in different clinical-biological situations. Leukemia 2001; 15: 292.
6. Thiede C, Bornhauser M, Oelschlagel U, Brendel C, Leo R, Daxberger H et al. Sequential monitoring of chimaerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification short tandem repeat-markers. Leukemia 2001; 15: 293-302.
7. Thiede C, Lion T. Quantitative analysis of chimerism after allogeneic stem cell transplantation using multiplex PCR amplification of short tandem repeat markers and fluorescence detection. Leukemia 2001; 15: 303-306.
8. Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D et al. Analysis of chimaerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001; 15: 307-310.
9. Lion T, Muller-B N. Chimerism testing after allogeneic stem cell transplantation: Importance of timing and optimal technique for chimerism testing in different clinical-biological situations. Leukemia 2001; 15: 1966.
10. Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): chimaerism testing as a guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967-1975.
11. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O. Leukemia lineage-specific chimaerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976-1985.
12. Gonzalez M, Lopez-Perez R, Garcia-Sanz R, Perez-Simon JA, San Miguel JF. Debate round-table: Comments concerning chimerism studies. Leukemia 2001; 5: 1986-1988.
13. Klingebiel T, Niethammer D, Dietz K, Bader P. Progress in chimerism analysis in childhood malignancies - the dilemma of biostatistical considerations and ethical implications. Leukemia 2001; 15: 1989-1991 (Erratum in: Leukemia 16(5): 972, 2002).
14. Lawler M. Prospective chimerism analysis, the time is now but can we respond? Leukemia 2001; 15: 1992-1994.
15. Biondi A, Balduzzi A. Questions on chimerism analysis after stem cell transplantation. Leukemia 2001; 15: 1995.
16. Schaap N, Schattenberg A, Mensink E, Preijers F, Hillegers M, Knops R et al. Long-term follow-up of persisting mixed chimaerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia 2002; 16: 13-21.
17. Lion T, Muller-B N. Chimerism testing after allogeneic stem cell transplantation: Importance of timing and optimal technique for chimerism testing in different clinical-biological situations. Leukemia 2002; 16: 1412.
18. Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I et al. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis. Leukemia 2002; 16 (8): 1413-1418 (Method in Focus pp 1419-22).
19. Perez-Simon JA, Caballero D, Diez-Campelo M, Lopez-Perez R, Mateos G, Canizo C et al. Chimaerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423-1431.
20. Lion T, Muller B N. Chimerism testing after allogeneic stem cell transplantation: Importance of timing and optimal technique for chimerism testing in different clinical-biological situations. Leukemia 2003; 17: 220.
21. Schraml E, Lion T. Interference of dye-associated fluorescence signals with quantitative analysis of chimerism by capillary electrophoresis. Leukemia 2003; 17: 221-223.
22. Schraml E, Daxberger H, Watzinger F, Lion T. Quantitative analysis of chimaerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: The Vienna experience. Leukemia 2003; 17: 224-227.
23. Chalandon Y, Vischer S, Helg C, Chapuis B, Roosnek E. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: The Geneva experience. Leukemia 2003; 17: 228-231.
24. Koehl U, Beck O, Esser R, Seifried E, Klingebiel T, Schwabe D et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: The Frankfurt experience. Leukemia 2003; 17: 232-236.
25. Kreyenberg H, Holle W, Mohrle S, Niethammer D, Bader P. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: The Tuebingen experience. Leukemia 2003; 17: 237-240.
26. Acquaviva C, Duval M, Mirebeau D, Bertin R, Cave H. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: The Paris-Robert Debre experience. Leukemia 2003; 17: 241-246.
27. Hancock JP, Goulden NJ, Oakhill A, Steward CG. Quantitative analysis of chimaerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite PCR. Leukemia 2003; 17: 247-251.
28. Lion T. Summary: Reports on quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection. Leukemia 2003; 17: 252-254.
29. Lion T, Muller B N. Chimerism testing after allogeneic stem cell transplantation: Importance of timing and optimal technique for testing in different clinical-biological situations. Leukemia 2003; 17: 612.
30. Fernandez-Aviles F, Urbano-Ispizua A, Aymerich M, Colomer D, Rovira M, Martinez C et al. Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood. Leukemia 2003; 17: 613-620.
31. Maas F, Schaap N, Kolen S, Zoetbrood A, Buno I, Dolstra H et al. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia 2003; 17: 621-629 (Method in Focus pp 630-633; Erratum in: Leukemia. 18(3):663, 2004).
32. Matthes-Martin S, Lion T, Haas OA, Frommlet F, Daxberger H, König M et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: Potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 2003; 17: 1934-1942.
33. Kristt D, Stein J, Yaniv I, Klein T. Interactive ChimerTrack software facilitates computation, visual displays and long-term tracking of chimeric status based on STRs. Leukemia 2004; 18: 909-911.
34. Lion T, Muller B N. Chimerism testing after allogeneic stem cell transplantation: Importance of timing and optimal technique for testing in different clinical-biological situations. Leukemia 2005; 19: 335.
35. Jimenez-Velasco A, Barrios M, Roman-Gomez J, Navarro G, Buno I, Castillejo JA et al. Reliable quantification of hematopoietic chimerism after alloggneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. Leukemia 2005; 19: 336-343.
36. Tilanus M. Short tandem repeat markers in diagnostics: What's in a repeat? Leukemia 2006.
37. Watzinger F, Lion T, Steward C, on behalf of the Eurochimerism Consortium. The RSD code: Proposal for a nomenclature of allelic configurations in STR-PCR based chimerism testing after allogeneic stem cell transplantation. Leukemia 2006.